biostudies-arrayexpressLara BuermannHomo sapienshttps://www.ebi.ac.uk/biostudies/studies/E-MTAB-14594The clinical utility of T-cell agonistic antibodies in cancer therapy, much less their ability to stimulate intratumoral T-cells in patients, has eluded us. T-cell agonistic antibodies such as anti-CD27 can induce clinically meaningful anti-tumor activity. The combination of anti-CD27 agonist varlilumab and tumor-depleting anti-CD20 rituximab was investigated in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) (RiVa trial;NCT03307746). Our experiments detail RNA-seq data from 21 B-cell NHL patients, including both pre and on-treatment biopsies taken from lymph nodes.biostudies-arrayexpressLibrary Construction - Sample library preparation was performed and quality checked by the Oxford Genomics Centre (OGC).Sequencing - Adapter-ligated libraries were sequenced by OGC with a 150 bp paired-end read configuration, using the Illumina NovaSeq 6000. All sample sequencing was paired-end.Nucleic Acid Extraction - Total RNA was isolated and processed using the Maxwell® RSC simplyRNA Cells and simplyRNA Tissue kits (Promega, Madison) following manufacturer’s instructions, and quantified and measured with Bioanalyser (Agilent Biosystems, Santa Clara).Sample Collection - Fresh cores of tumors cores collected in RPMI were minced into 1 mm3 pieces or smaller using a scalpel and added to Liberase™ DL (Roche, Basel) RPMI for 15 minutes at 37 oC on an orbital shaker at 250 rpm. The sample mixture was then passed through a 70 µm filter, washed four times, red cell lysis (Qiagen) undertaken, and washed twice more. Resultant single cell suspension was cryopreserved in 50% v/v human AB serum (Sigma, Burlington), 40% supplemented RPMI and 10% v/v DMSO (Sigma, Burlington).OrganizationMINSEQE ScoreAssays and DataProcessed DataMAGE-TAB FilesData Transformation - Raw reads were converted to transcript-level counts and TPM (transcripts per million) using Kallisto v0.46 together with Gencode v31 human transcript reference. Counts and TPM were summarized at the gene level using tximport v1.14.MetabolomicsUnknownTranscriptomicsGenomicsProteomicsIllumina NovaSeq 6000RNA-seq of coding RNAHomo sapiensSean LimLara BuermannfalseAnti-CD27 immunotherapy induces intratumoral immunostimulation in B-cell lymphoma: the multicenter RiVa trial (RNA-Seq Data for RiVa)The clinical utility of T-cell agonistic antibodies in cancer therapy, much less their ability to stimulate intratumoral T-cells in patients, has eluded us. T-cell agonistic antibodies such as anti-CD27 can induce clinically meaningful anti-tumor activity. The combination of anti-CD27 agonist varlilumab and tumor-depleting anti-CD20 rituximab was investigated in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) (RiVa trial;NCT03307746). Our experiments detail RNA-seq data from 21 B-cell NHL patients, including both pre and on-treatment biopsies taken from lymph nodes.2025-08-09T00:00:00Z2025-08-10T00:00:48.642Z2024-11-06T17:27:36.427ZE-MTAB-14594ERP165983EFO_0002944EFO_0004170EFO_0005518EFO_0003816EFO_0003738EFO_0004184